SORL1 and Alzheimer disease: Collectively, our results support the conclusion that SORL1, and the retromer-dependent pathway in which it functions, is a valid therapeutic target and interventions directed at this pathway may ameliorate endosomal recycling defects that seem to act as, at least, one primary driver of AD.